Recent Updates
Recently added Catalysts
RARE

Ultragenyx Reports Preliminary 2024 Revenue, Financial Guidance for 2025, Pipeline Updates, and 2025 Milestones

Sunday, January 12, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Ultragenyx Reports Preliminary 2024 Revenue, Financial Guidance for 2025, Pipeline Updates, and 2025 Milestones
Price reaction · baseline $42.07 (2025-01-10 close) · clean, no other RARE news in the window
day 0 close · peak
+2.6%

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+43%
120-day peak, hindsight
Typical move
2.9%
average across 6 past catalysts
Cash runway
~13 mo
Low dilution risk
Lead asset
BPS804
Phase 2 · Hypophosphatasia

Full Press Release Details

Ultragenyx Reports Preliminary 2024 Revenue, Financial Guidance for 2025, Pipeline Updates, and 2025 Milestones.
ShareAdd on Google
Tags: RARE Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Jan 12, 2025

Biotech snapshot

Cash runway
$436M liquidity · $32M/mo burn
~13 mo
Low dilution risk
Lead asset
BPS804Phase 2
Hypophosphatasia →

Catalyst track record

+43%
best trade around RARE's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for RARE.

See every catalyst's timing & PoA →